 All patients will receive TACLONEX. To evaluate the safety of TACLONEX ointment, all adverse events will be recorded. In addition, any systemic absorption of the active components, betamethasone dipropionate and calcipotriene, will be evaluated by assessing adrenal function using CORTROSYNTM test and calcium metabolism by measuring serum calcium and the urinary calcium:creatinine ratio, respectively. 